ABVC
HEALTHCAREABVC BioPharma Inc
$1.10+0.07 (+6.80%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ABVC Today?
No stock-specific AI insight has been generated for ABVC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.88$5.48
$1.10
Fundamentals
Market Cap$28M
P/E Ratio—
EPS$-0.39
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume160K
Avg Volume (10D)—
Shares Outstanding25.6M
ABVC News
20 articles- ABVC BioPharma Reports 2025 Form 10-KYahoo Finance·Mar 3, 2026
- ABVC BioPharma Provides Corporate and Structural UpdateYahoo Finance·Feb 24, 2026
- ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United StatesYahoo Finance·Dec 2, 2025
- ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030Yahoo Finance·Nov 26, 2025
- ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already ReceivedYahoo Finance·Nov 21, 2025
- ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 MillionYahoo Finance·Nov 18, 2025
- ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025Yahoo Finance·Nov 3, 2025
- ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950Yahoo Finance·Oct 31, 2025
- ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and OncologyYahoo Finance·Oct 17, 2025
- ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) ProductionYahoo Finance·Oct 8, 2025
- ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression TherapiesYahoo Finance·Sep 23, 2025
- ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business ModelYahoo Finance·Sep 19, 2025
- ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025Yahoo Finance·Aug 29, 2025
- BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing CollaborationYahoo Finance·Aug 27, 2025
- ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing DealYahoo Finance·Aug 22, 2025
- ABVC BioPharma First Half 2025 Earnings: US$0.19 loss per share (vs US$0.36 loss in 1H 2024)Yahoo Finance·Aug 15, 2025
- ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025Yahoo Finance·Aug 14, 2025
- BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff ShiftsYahoo Finance·Aug 8, 2025
- ABVC BioPharma Gains Confidence From International Investors to Support Growth PathYahoo Finance·Aug 6, 2025
- OncoX Deepens ABVC AllianceYahoo Finance·Aug 1, 2025
All 20 articles loaded
Price Data
Open$1.08
Previous Close$1.03
Day High$1.09
Day Low$1.02
52 Week High$5.48
52 Week Low$0.88
52-Week Range
$0.88$5.48
$1.10
Fundamentals
Market Cap$28M
P/E Ratio—
EPS$-0.39
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume160K
Avg Volume (10D)—
Shares Outstanding25.6M
About ABVC BioPharma Inc
American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—